Company Overview and News

Admedus files three new patents in the US for heart valve device

Admedus Ltd (ASX:AHZ) has filed three new provisional patent applications in the US as part of its transcatheter aortic valve replacement (TAVR) research and development project.

Admedus progressing to animal trials of its unique heart valve device

Admedus Ltd (ASX:AHZ) is entering the next stage in the development of its Transcatheter Aortic Valve Replacement (TAVR) project by signing an agreement to commence animal trials in a leading European laboratory.

Admedus signs deal to market its heart tissue products in Spain and Portugal

Admedus Ltd (ASX:AHZ) has signed an exclusive distribution agreement with leading healthcare group, Cardiva, to market and supply its ADAPT® tissue products in Spain and Portugal.

Admedus using capital raised to advance product development and share price growth

Admedus Ltd (ASX:AHZ) chief executive Wayne Paterson updates Proactive Investors on product development, a major agreement, key executive appointments, and strategic financing decisions.

Admedus secures $6 million to expand medical technologies strategy

Admedus Ltd (ASX:AHZ) has raised about $6 million after securing commitments from institutional and sophisticated investors in a placement at 30 cents per share.

Admedus enters trading halt ahead of capital raising

Admedus Ltd (ASX:AHZ) has been granted a trading halt by the ASX pending the release of further details regarding a capital raising.

Admedus has healthy mix of reliable Infusion earnings and strong revenue growth from ADAPT

Admedus Ltd (ASX:AHZ) is reaping the benefits of an impressive year in terms of execution as it delivers on several key initiatives and invests in long-term sustainability.

Admedus appoints medtech expert Michael Oswell as vice president, development

Admedus Ltd (ASX:AHZ) has appointed Michael Oswell to the newly created role of vice president, development.

Admedus enters into letter of intent to arrange alternative funding for immunotherapies division

Admedus Ltd’s (ASX:AHZ) subsidiary Admedus Vaccines Pty Ltd has entered into a letter of intent (LOI) with Hong Kong-based investor Star Bright Holding Ltd as part of negotiations for an ongoing funding arrangement.

Admedus takes significant step forward in developing unique heart valve device

Admedus Ltd (ASX:AHZ) has submitted several new provisional patent applications in the US for further development of its novel Transcatheter Aortic Valve Replacement (TAVR) device.

Admedus advances in North America with more products and markets on the horizon

Wayne Paterson, chief executive of Admedus Ltd (ASX:AHZ), speaks about flagship ADAPT tissue products securing regulatory approval in Canada and a distribution network in the U.S..

Admedus heart valve device in development passes key milestone

Admedus Ltd (ASX:AHZ) has passed a key development milestone for its transcatheter aortic valve replacement (TAVR) device project.

Admedus enters agreement opening sales channel to 1,500 hospitals

Admedus Ltd (ASX:AHZ) has entered a purchasing agreement allowing it to promote its flagship ADAPT® tissue products, CardioCel® and VascuCel®, to more than 1,500 hospitals.

Admedus secures regulatory approval in Canada for heart tissue products

Admedus Ltd (ASX:AHZ) has received regulatory approval to introduce its CardioCel 3D® and VascuCel® products in Canada, alongside CardioCel® which is already available.

Admedus Ltd moving up the value chain and preparing for 'pivotal' year

Wayne Paterson, chief executive of Admedus Ltd (ASX:AHZ), spoke to Proactive's Andrew Scott following the release of their quarterly update.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...